Sequencing is used to identify novel drug targets and genetically stratifying clinical trial patients, improving the power of precision medicine. However, the global disparity of genomic technologies is increasing. How will this affect drug development, particularly for non-European ethnicities? Why is it important to have a global context for targeted therapies?